The ACME Laboratories Ltd. (DSE:ACMELAB)
Bangladesh
· Delayed Price · Currency is BDT 74.90
-0.10 (-0.13%)
At close: Apr 9, 2025
The ACME Laboratories Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| Revenue | 33,499 | 31,932 | 26,948 | 23,858 | 20,770 | 19,004 | Upgrade
|
| Revenue Growth (YoY) | 13.96% | 18.50% | 12.95% | 14.87% | 9.29% | 16.53% | Upgrade
|
| Cost of Revenue | 19,461 | 18,715 | 16,045 | 14,458 | 12,772 | 11,766 | Upgrade
|
| Gross Profit | 14,039 | 13,216 | 10,902 | 9,401 | 7,998 | 7,237 | Upgrade
|
| Selling, General & Admin | 8,068 | 7,539 | 6,424 | 5,381 | 4,457 | 3,551 | Upgrade
|
| Other Operating Expenses | 3.9 | 3.9 | 3.89 | 3.73 | -96.44 | 5.73 | Upgrade
|
| Operating Expenses | 8,072 | 7,543 | 6,428 | 5,385 | 4,360 | 3,556 | Upgrade
|
| Operating Income | 5,967 | 5,673 | 4,474 | 4,016 | 3,638 | 3,681 | Upgrade
|
| Interest Expense | -2,684 | -2,283 | -1,426 | -1,293 | -1,585 | -1,765 | Upgrade
|
| Interest & Investment Income | 5.55 | 5.55 | 6.99 | 5.73 | 18.01 | 31.96 | Upgrade
|
| Currency Exchange Gain (Loss) | -388.43 | -388.43 | -197.48 | -91.93 | 18.62 | 38.11 | Upgrade
|
| Other Non Operating Income (Expenses) | 348.95 | 199.91 | 32.71 | 55.34 | -16.38 | -9.64 | Upgrade
|
| EBT Excluding Unusual Items | 3,249 | 3,207 | 2,891 | 2,692 | 2,073 | 1,976 | Upgrade
|
| Gain (Loss) on Sale of Assets | -3.94 | -3.94 | 3.86 | 1.31 | 0.18 | 3.25 | Upgrade
|
| Asset Writedown | - | - | -1.37 | - | - | - | Upgrade
|
| Other Unusual Items | 0.65 | 0.65 | - | - | - | - | Upgrade
|
| Pretax Income | 3,246 | 3,204 | 2,893 | 2,693 | 2,073 | 1,979 | Upgrade
|
| Income Tax Expense | 855.04 | 747.54 | 589.65 | 582.25 | 504.27 | 528.93 | Upgrade
|
| Net Income | 2,391 | 2,456 | 2,304 | 2,111 | 1,569 | 1,450 | Upgrade
|
| Net Income to Common | 2,391 | 2,456 | 2,304 | 2,111 | 1,569 | 1,450 | Upgrade
|
| Net Income Growth | 0.68% | 6.62% | 9.13% | 34.52% | 8.19% | 0.70% | Upgrade
|
| Shares Outstanding (Basic) | 212 | 212 | 212 | 212 | 212 | 212 | Upgrade
|
| Shares Outstanding (Diluted) | 212 | 212 | 212 | 212 | 212 | 212 | Upgrade
|
| EPS (Basic) | 11.30 | 11.61 | 10.89 | 9.98 | 7.42 | 6.85 | Upgrade
|
| EPS (Diluted) | 11.30 | 11.61 | 10.89 | 9.98 | 7.42 | 6.85 | Upgrade
|
| EPS Growth | 0.68% | 6.62% | 9.13% | 34.52% | 8.26% | 0.63% | Upgrade
|
| Free Cash Flow | -1,830 | -2,162 | -4,001 | -615.35 | 915.26 | -958.2 | Upgrade
|
| Free Cash Flow Per Share | -8.65 | -10.22 | -18.91 | -2.91 | 4.33 | -4.53 | Upgrade
|
| Dividend Per Share | 3.500 | 3.500 | 3.300 | 3.000 | 2.500 | 2.500 | Upgrade
|
| Dividend Growth | 6.06% | 6.06% | 10.00% | 20.00% | - | -28.57% | Upgrade
|
| Gross Margin | 41.91% | 41.39% | 40.46% | 39.40% | 38.51% | 38.08% | Upgrade
|
| Operating Margin | 17.81% | 17.77% | 16.60% | 16.83% | 17.52% | 19.37% | Upgrade
|
| Profit Margin | 7.14% | 7.69% | 8.55% | 8.85% | 7.56% | 7.63% | Upgrade
|
| Free Cash Flow Margin | -5.46% | -6.77% | -14.85% | -2.58% | 4.41% | -5.04% | Upgrade
|
| EBITDA | 7,555 | 7,227 | 5,882 | 5,368 | 4,970 | 4,866 | Upgrade
|
| EBITDA Margin | 22.55% | 22.63% | 21.83% | 22.50% | 23.93% | 25.61% | Upgrade
|
| D&A For EBITDA | 1,588 | 1,554 | 1,407 | 1,352 | 1,332 | 1,185 | Upgrade
|
| EBIT | 5,967 | 5,673 | 4,474 | 4,016 | 3,638 | 3,681 | Upgrade
|
| EBIT Margin | 17.81% | 17.77% | 16.60% | 16.83% | 17.52% | 19.37% | Upgrade
|
| Effective Tax Rate | 26.35% | 23.33% | 20.38% | 21.62% | 24.32% | 26.72% | Upgrade
|
| Advertising Expenses | - | 178.77 | 146.59 | 138.99 | - | - | Upgrade
|
Updated Feb 2, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.